Informações:
Falhas:
ID
20601
Descrição
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00529763
Link
https://clinicaltrials.gov/show/NCT00529763
Palavras-chave
Versões (1)
- 06/03/2017 06/03/2017 -
Transferido a
6 de março de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Leukemia NCT00529763
Eligibility Leukemia NCT00529763
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00529763
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
informed consent
Item
signed written informed consent
boolean
C0021430 (UMLS CUI [1])
age, gender
Item
men and women, ages 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0079399 (UMLS CUI [2])
Chronic phase; Myeloid Leukemia, Chronic | Advanced phase; Myeloid Leukemia, Chronic | Acute lymphocytic leukemia
Item
subjects with chronic phase (cp) or advanced disease (ad) chronic myeloid leukemia (cml)/ph+ acute lymphoblastic leukemia (ph+ all)
boolean
C0457343 (UMLS CUI [1,1])
C0023473 (UMLS CUI [1,2])
C0205179 (UMLS CUI [2,1])
C0023473 (UMLS CUI [2,2])
C0023449 (UMLS CUI [3])
C0023473 (UMLS CUI [1,2])
C0205179 (UMLS CUI [2,1])
C0023473 (UMLS CUI [2,2])
C0023449 (UMLS CUI [3])
intolerance to substance; imatinib | Treatment-Resistant; imatinib
Item
subjects resistant/intolerant to imatinib
boolean
C1744706 (UMLS CUI [1,1])
C0935989 (UMLS CUI [1,2])
C4020575 (UMLS CUI [2,1])
C0935989 (UMLS CUI [2,2])
C0935989 (UMLS CUI [1,2])
C4020575 (UMLS CUI [2,1])
C0935989 (UMLS CUI [2,2])
ecog
Item
1. eastern cooperative oncology group (ecog) performance status (ps) score 0-2
boolean
C1520224 (UMLS CUI [1])
liver function
Item
2. adequate hepatic function
boolean
C0232741 (UMLS CUI [1])
renal function
Item
3. adequate renal function
boolean
C0232804 (UMLS CUI [1])
Sodium measurement | Potassium measurement | Magnesium measurement | Phosphate measurement | Calcium measurement
Item
4. sodium, potassium, magnesium, phosphorus, calcium higher or equal than the lower limit of normal range
boolean
C0337443 (UMLS CUI [1])
C0202194 (UMLS CUI [2])
C0373675 (UMLS CUI [3])
C0523826 (UMLS CUI [4])
C0201925 (UMLS CUI [5])
C0202194 (UMLS CUI [2])
C0373675 (UMLS CUI [3])
C0523826 (UMLS CUI [4])
C0201925 (UMLS CUI [5])
Female of child bearing age | Contraceptive methods
Item
women of child bearing potential who are not using adequate birth control
boolean
C1960468 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
pregnancy, breast feeding
Item
women who are pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
subjects eligible for stem cell transplantation
Item
subjects eligible for stem cell transplantation
boolean
C1504389 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C1548635 (UMLS CUI [1,2])
serious uncontrolled medical disorder or active infection
Item
serious uncontrolled medical disorder or active infection
boolean
C0012634 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205177 (UMLS CUI [2,2])
C0439801 (UMLS CUI [3,1])
C0525058 (UMLS CUI [3,2])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205177 (UMLS CUI [2,2])
C0439801 (UMLS CUI [3,1])
C0525058 (UMLS CUI [3,2])
cardiovascular disease
Item
uncontrolled or significant cardiovascular disease
boolean
C0007222 (UMLS CUI [1])
concurrent incurable malignancy
Item
concurrent incurable malignancy other than cml
boolean
C0006826 (UMLS CUI [1,1])
C0175969 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
C0175969 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
imatinib | Interferon | Cytarabine | Antineoplastic Agents | hydroxyurea | dasatinib; Prior Therapy
Item
subjects who received imatinib, interferon, cytarabine within 7 days or other antineoplastic agents other than hydroxyurea within 14 days before dasatinib, dasatinib in the past
boolean
C0935989 (UMLS CUI [1])
C3652465 (UMLS CUI [2])
C0010711 (UMLS CUI [3])
C0003392 (UMLS CUI [4])
C0020402 (UMLS CUI [5])
C1455147 (UMLS CUI [6])
C1514463 (UMLS CUI [7])
C3652465 (UMLS CUI [2])
C0010711 (UMLS CUI [3])
C0003392 (UMLS CUI [4])
C0020402 (UMLS CUI [5])
C1455147 (UMLS CUI [6])
C1514463 (UMLS CUI [7])
medical history hemorrhage
Item
history of significant bleeding unrelated to cml
boolean
C0262926 (UMLS CUI [1,1])
C0019080 (UMLS CUI [1,2])
C0019080 (UMLS CUI [1,2])